Two weeks after first unveiling results, the full Oxford University and AstraZeneca’s Phase II/III COVID-19 vaccine studies have been published in The Lancet, but the paper has uncovered more shortcomings in the data to add to doubts raised two week ago when they were first presented.
Regulators in the UK, European Union and India are already reviewing the results, however, and may decide to grant emergency...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
